Stockscreener 앱 받기
19.79
3.18%
0.61
시간 외 거래:
19.50
-0.29
-1.47%
전일 마감가:
$19.18
열려 있는:
$19.27
하루 거래량:
2.43M
Relative Volume:
0.78
시가총액:
$2.09B
수익:
$2.18B
순이익/손실:
$-64.32M
주가수익비율:
-20.53
EPS:
-0.9641
순현금흐름:
$91.18M
1주 성능:
+10.13%
1개월 성능:
+25.65%
6개월 성능:
-15.64%
1년 성능:
+14.26%
1일 변동 폭
$18.63
$19.85
1주일 범위
$17.45
$19.85
52주 변동 폭
$10.41
$25.32
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
19.79 | 2.02B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Sarepta Therapeutics
Sarepta Refused FDA’s Request to Halt Elevidys Shipments - MSN
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPTSarepta Therapeutics Inc Volatility & Greeks - Finviz
ETFs Investing in Sarepta Therapeutics, Inc. Stocks - TradingView
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally - AlphaStreet
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sahm
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail - BioSpace
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5 - Moomoo
SRPT Stock Quote Price and Forecast - CNN
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne - BioPharm International
FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments - Intellectia AI
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies - Stocktwits
Mizuho reiterates Sarepta stock rating after FDA filing acceptance By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Sarepta stock jumps as FDA accepts DMD drug applications - Investing.com UK
Sarepta stock jumps as FDA accepts DMD drug applications By Investing.com - Investing.com Nigeria
Sarepta (SRPT) Seeks Traditional Approval for Duchenne Therapies - GuruFocus
FDA accepts Sarepta filings for two Duchenne therapies - Investing.com
FDA accepts Sarepta filings for two Duchenne therapies By Investing.com - Investing.com Canada
FDA to review Sarepta’s Duchenne drugs, with decision due Feb. 28, 2027 - Stock Titan
Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation - Sahm
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Value Benchmark - marketscreener.com
Sarepta Therapeutics (SRPT) Stock Analysis: Unveiling a 30% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Dynamic Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Value Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutic - The National Law Review
Investors SueWallSt as Sarepta Therapeutics, Inc. Faces Securities Fraud Allegations - The National Law Review
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Did You Lose Money on Sarepta Therapeutics, Inc. (SRPT)? Levi & K - The National Law Review
Class Action Lawsuit Filed: Sarepta Therapeutics, Inc. (SRPT) – Join by August 25, 2025Contact Levi & Korsinsky - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - The National Law Review
Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SR - The National Law Review
Sarepta Therapeutics Rises As Gene Therapy Outlook Strengthens - StocksToTrade
SRPT Rises As Sarepta Gains Gene Therapy Momentum - timothysykes.com
SRPT Jumps As Sarepta Wins Tailwinds In Gene Therapy - StocksToTrade
Sarepta Therapeutics Stock Firms As Gene Therapy Tailwinds Build - timothysykes.com
Sarepta Therapeutics, Inc. Actuals & Estimates (BMV:SRPT) - TradingView
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):